Home FOR PATIENTS
Resources

This link will redirect you to livercancertrials.com

Percutaneous Hepatic Perfusion (PHP)™, or The Delcath PHP System™, or allows the delivery of very high doses of anticancer drugs to the liver in order to kill tumor cells, but drastically reduces the amount of those drugs entering the general circulation where they can cause side effects.

NOTE: PHP is investigational and has not been approved by the US Food and Drug Administration.

 

 

Other Methods of Treatment

Resources
Other liver cancer treatments include gene therapy, hyperthermia and the use of biological response modulators, monoclonal antibodies and liposomes. Many of these treatment options are experimental, and their effectiveness is either limited or unknown, and many are not repeatable or have dose limiting side-effects.
 

Surgically Isolated Perfusion

Resources

Physicians have made efforts to address the trade-off between the efficacy of intravenous chemotherapy treatment and its side effects. The overall goal has been to isolate the liver from the general circulatory system and to achieve a targeted delivery of chemotherapy agents to the liver. Surgically isolated perfusion, also known as IHP, involves an open surgical procedure in which arteries and veins supplying the liver are physically clamped, and blood flow is diverted from the liver while infusing high dosages of chemotherapy agents into the liver.

Read more...
 

Implanted Infusion Pumps

Resources
Implanted infusion pumps target the delivery of chemotherapy agents to the tumor. Implantable pumps may be used to treat colorectal cancer which has metastasized to the liver. The pump is surgically implanted under the skin and delivers regular doses of chemotherapeutic agents in a targeted area over time. This pump, however, lacks a means of preventing the entry of chemotherapy agents into the patient's general circulation after it passes through the liver. As a result, this technique does not enable physicians to prescribe higher doses of chemotherapy.
 

Hepatic Artery Infusion

Resources
Hepatic artery infusion involves the injection of chemotherapeutic drugs directly into the artery supplying the liver. Because the chemotherapy agents pass from the liver into the patient's general circulation, hepatic arterial infusion has similar toxicities to systemic administration and does not enable physicians to prescribe higher doses of chemotherapy.
 

Liver Transplant

Resources
Transplanting a healthy donor liver into a patient with liver tumors is rarely performed due to the low availability of donor organs and the high probability of tumor recurrence within the transplanted liver. It is an option for those that have small and early-stage tumors.
 
More Articles...
  • «
  •  Start 
  •  Prev 
  •  1 
  •  2 
  •  3 
  •  Next 
  •  End 
  • »
Page 1 of 3

Phase II Trial Centers

MARYLAND
National Cancer Institute
Dr. Marybeth Hughes
(301) 402-4396
hughesm@mail.nih.gov

Phase III Trial Centers

CALIFORNIA
John Wayne Cancer Institute
Dr. Mark Faries
(310) 582-7020
FariesM@JWCI.ORG

 

COLORADO
Swedish Medical Center
Dr. Charles Nutting
(303) 806-7418
Charlie.Nutting@riaco.com

 

FLORIDA
Moffitt Cancer Center
Dr. Jonathan Zager
(813) 745-1085
jonathan.zager@moffitt.org

 

MARYLAND
National Cancer Institute
Dr. Marybeth Hughes
(301) 402-4396
hughesm@mail.nih.gov

 

MARYLAND
University of Maryland
Dr. Richard Alexander
(410) 328-7680
HRAlexander@smail.umaryland.edu

 

NEW JERSEY
Morristown Memorial Hospital
Dr. Eric Whitman
(973) 971-7111
eric.whitman@atlantichealth.org

 

NEW YORK
Albany Medical Center
Dr. Gary Siskin
(518) 262-2397
SiskinG@mail.amc.edu

 

OHIO
Ohio State University
Dr. Mark Bloomston
(614) 293-4583
mark.bloomston@osumc.edu

 

 

PENNSYLVANIA
St. Luke's Cancer Center
Dr. Sanjiv Agarwala
(610) 954-2145
AgarwaS@slhn.org

 

TEXAS
University of Texas Medical Branch
Dr. Orhan Ozkan
(409) 772-9202
oozkan@utmb.edu

 

 PENNSYLVANIA
University of Pittsburgh Medical Center
Dr. James Pingpank
(412) 692-2852
pingpankjf@upmc.edu